AAPL   381.50 (-0.32%)
MSFT   213.22 (-0.51%)
FB   241.66 (-1.16%)
AMZN   3,183.53 (+0.03%)
NVDA   421.15 (+0.19%)
BABA   260.70 (-0.34%)
GE   6.64 (+0.91%)
ACB   11.91 (+1.19%)
GILD   76.39 (+2.25%)
DIS   118.30 (+1.27%)
NFLX   540.20 (+6.39%)
AAPL   381.50 (-0.32%)
MSFT   213.22 (-0.51%)
FB   241.66 (-1.16%)
AMZN   3,183.53 (+0.03%)
NVDA   421.15 (+0.19%)
BABA   260.70 (-0.34%)
GE   6.64 (+0.91%)
ACB   11.91 (+1.19%)
GILD   76.39 (+2.25%)
DIS   118.30 (+1.27%)
NFLX   540.20 (+6.39%)
AAPL   381.50 (-0.32%)
MSFT   213.22 (-0.51%)
FB   241.66 (-1.16%)
AMZN   3,183.53 (+0.03%)
NVDA   421.15 (+0.19%)
BABA   260.70 (-0.34%)
GE   6.64 (+0.91%)
ACB   11.91 (+1.19%)
GILD   76.39 (+2.25%)
DIS   118.30 (+1.27%)
NFLX   540.20 (+6.39%)
AAPL   381.50 (-0.32%)
MSFT   213.22 (-0.51%)
FB   241.66 (-1.16%)
AMZN   3,183.53 (+0.03%)
NVDA   421.15 (+0.19%)
BABA   260.70 (-0.34%)
GE   6.64 (+0.91%)
ACB   11.91 (+1.19%)
GILD   76.39 (+2.25%)
DIS   118.30 (+1.27%)
NFLX   540.20 (+6.39%)
Log in

NASDAQ:APTXAptinyx Stock Price, Forecast & News

$4.56
-0.11 (-2.36 %)
(As of 07/10/2020 01:20 PM ET)
Add
Compare
Today's Range
$4.53
Now: $4.56
$4.77
50-Day Range
$3.53
MA: $4.10
$4.99
52-Week Range
$1.60
Now: $4.56
$5.28
Volume5,327 shs
Average Volume596,864 shs
Market Capitalization$208.21 million
P/E RatioN/A
Dividend YieldN/A
Beta1.48
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder. The company has a collaboration agreement with Allergan plc. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois.
Read More
Aptinyx logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.41 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:APTX
CUSIPN/A
CIKN/A
Phone847-871-0377

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.67 million
Book Value$2.31 per share

Profitability

Net Income$-57,410,000.00
Net Margins-1,540.42%

Miscellaneous

EmployeesN/A
Market Cap$208.21 million
Next Earnings Date8/10/2020 (Estimated)
OptionableNot Optionable

Receive APTX News and Ratings via Email

Sign-up to receive the latest news and ratings for APTX and its competitors with MarketBeat's FREE daily newsletter.

Aptinyx (NASDAQ:APTX) Frequently Asked Questions

How has Aptinyx's stock been impacted by COVID-19 (Coronavirus)?

Aptinyx's stock was trading at $2.43 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, APTX shares have increased by 87.7% and is now trading at $4.56. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Aptinyx?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptinyx in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aptinyx.

When is Aptinyx's next earnings date?

Aptinyx is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Aptinyx.

How were Aptinyx's earnings last quarter?

Aptinyx Inc (NASDAQ:APTX) announced its quarterly earnings data on Thursday, May, 14th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by $0.01. The company earned $0.82 million during the quarter, compared to the consensus estimate of $0.91 million. Aptinyx had a negative net margin of 1,540.42% and a negative return on equity of 47.99%. View Aptinyx's earnings history.

What price target have analysts set for APTX?

6 Wall Street analysts have issued 12-month price objectives for Aptinyx's stock. Their forecasts range from $7.00 to $15.00. On average, they anticipate Aptinyx's stock price to reach $9.67 in the next twelve months. This suggests a possible upside of 112.0% from the stock's current price. View analysts' price targets for Aptinyx.

Has Aptinyx been receiving favorable news coverage?

News stories about APTX stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Aptinyx earned a media sentiment score of 1.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about Aptinyx.

Are investors shorting Aptinyx?

Aptinyx saw a increase in short interest in June. As of June 30th, there was short interest totaling 659,300 shares, an increase of 115.4% from the June 15th total of 306,100 shares. Based on an average daily volume of 292,200 shares, the short-interest ratio is currently 2.3 days. Approximately 3.0% of the shares of the stock are sold short. View Aptinyx's Current Options Chain.

Who are some of Aptinyx's key competitors?

What other stocks do shareholders of Aptinyx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptinyx investors own include Onconova Therapeutics (ONTX), Opko Health (OPK), VBI Vaccines (VBIV), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Square (SQ) and vTv Therapeutics (VTVT).

Who are Aptinyx's key executives?

Aptinyx's management team includes the following people:
  • Dr. Norbert G. Riedel, Pres, CEO & Director (Age 61)
  • Dr. Joseph R. Moskal Ph.D., Chief Scientific Officer (Age 68)
  • Dr. Torsten Meldgaard Madsen, Chief Medical Officer (Age 51)
  • Mr. Ashish Khanna, CFO & Chief Bus. Officer (Age 43)
  • Ms. Betty Y. Jang, VP of Legal Affairs (Age 50)

When did Aptinyx IPO?

(APTX) raised $77 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,300,000 shares at $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

What is Aptinyx's stock symbol?

Aptinyx trades on the NASDAQ under the ticker symbol "APTX."

How do I buy shares of Aptinyx?

Shares of APTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aptinyx's stock price today?

One share of APTX stock can currently be purchased for approximately $4.56.

How big of a company is Aptinyx?

Aptinyx has a market capitalization of $208.21 million and generates $3.67 million in revenue each year. The company earns $-57,410,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis.

What is Aptinyx's official website?

The official website for Aptinyx is www.aptinyx.com.

How can I contact Aptinyx?

Aptinyx's mailing address is 909 DAVIS STREET SUITE 600, EVANSTON IL, 60201. The company can be reached via phone at 847-871-0377 or via email at [email protected]

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.